腹膜透析患者补充肉碱对贫血的影响：一项回顾性观察研究。

Change in Anemia by Carnitine Supplementation in Patients Undergoing Peritoneal Dialysis: A Retrospective Observational Study.

作者信息

Kaneko Shohei, Yanai Katsunori, Kitano Taisuke, Miyazawa Haruhisa, Hirai Keiji, Ookawara Susumu, Morishita Yoshiyuki

机构信息

Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

出版信息

Front Med (Lausanne). 2021 Nov 5;8:767945. doi: 10.3389/fmed.2021.767945. eCollection 2021.

DOI:10.3389/fmed.2021.767945

PMID:34805230

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8602557/

Abstract

Carnitine supplementation improves various dialysis-related symptoms including erythropoietin-resistant anemia in patients who are undergoing hemodialysis. However, the utility of carnitine supplementation in patients who are undergoing peritoneal dialysis (PD) is not fully understood. Thirteen patients undergoing PD [mean age: 54.2 ± 14.8 years, males: 9/13 (69%)] administered oral carnitine supplementation (mean dose: 9.1 ± 3.3 mg/kg/day) for 4-6 months were retrospectively investigated. Changes in serum carnitine levels and other clinical variables including the erythropoietin resistance index (ERI) were analyzed after carnitine supplementation. Carnitine supplementation increased serum total carnitine (48.5 ± 10.2 vs. 130.1 ± 37.2 μmol/L, < 0.01), free carnitine (31.1 ± 8.3 vs. 83.1 ± 24.6 μmol/L, < 0.01), and acyl carnitine (17.4 ± 2.8 vs. 46.9 ± 13.8, < 0.01) levels. The acyl carnitine/free carnitine ratio was not affected (0.6 ± 0.1 vs. 0.6 ± 0.1, = 0.75). Although the mean ERI was not affected by carnitine supplementation [13.7 ± 4.7 vs. 11.6 ± 3.4 IU/kg/(g/dL)/week, = 0.28], the ERI change rate was significantly decreased (1.00 ± 0.00 vs. 0.87 ± 0.11, < 0.01). Carnitine supplementation may improve erythropoietin resistance in patients who are undergoing PD.

摘要

补充肉碱可改善血液透析患者的各种透析相关症状，包括对促红细胞生成素抵抗的贫血。然而，补充肉碱在腹膜透析（PD）患者中的作用尚未完全明确。本研究回顾性调查了13例接受PD治疗的患者[平均年龄：54.2±14.8岁，男性：9/13（69%）]，给予口服补充肉碱（平均剂量：9.1±3.3mg/kg/天），持续4 - 6个月。分析补充肉碱后血清肉碱水平及其他临床变量的变化，包括促红细胞生成素抵抗指数（ERI）。补充肉碱可提高血清总肉碱水平（48.5±10.2 vs. 130.1±37.2μmol/L，<0.01）、游离肉碱水平（31.1±8.3 vs. 83.1±24.6μmol/L，<0.01）和酰基肉碱水平（17.4±2.8 vs. 46.9±13.8，<0.01）。酰基肉碱/游离肉碱比值未受影响（0.6±0.1 vs. 0.6±0.1，=0.75）。虽然补充肉碱对平均ERI无影响[13.7±4.7 vs. 11.6±3.4IU/kg/（g/dL）/周，=0.28]，但ERI变化率显著降低（1.00±0.00 vs. 0.87±0.1 l，<0.01）。补充肉碱可能改善接受PD治疗患者的促红细胞生成素抵抗。